Health Canada granted approval to partner Bausch Health Companies Inc and Glenmark Specialty SA, a subsidiary of the company, for Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray), Glenmark Pharmaceuticals said in a statement.
Source link
